Benign Prostatic Hyperplasia News

Q: I heard about a new long-acting medication for treatment of an enlarged prostate.

All amounts are in U.S. dollars QUEBEC CITY, Nov. 13 /CNW Telbec/ - AEterna Zentaris Inc.

Protox Therapeutics Inc. , a leader in the development of receptor targeted fusion proteins, today released third quarter 2008 financial results for the three months ended September 30, 2008 .

PATIENTS AND METHODS: The study included 80 patients with a diagnosis of BPH, but no history or symptoms of prostatitis.

From watching the advertisements that litter the evening network news, I sometimes wonder if the prostate gland is the only organ in the human body, worthy of note.

Main Category: Prostate / Prostate Cancer Also Included In: Urology / Nephrology Nymox Pharmaceutical Corporation announced today that the Company's latest multi-center U.S. study of NX-1207, its ...

Researchers from Dendreon Corporation today presented preclinical data on its lead small molecule candidate, D-3263, which targets Trp-p8 , supporting Trp-p8 as a therapeutic cancer target.

Nymox Pharmaceutical Corporation has announced that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia , is nearing completion.

While treatment options for prostate problems have expanded over the last few yearsthe German Institute for Quality and Efficiency in Health Care warns that some new surgical techniques are being heavily ...

Abstract Background: This report and a companion report describe a validation of the ability of serum proteomic profiling via SELDI-TOF mass spectrometry to detect prostatic cancer.

The German Institute for Quality and Efficiency in Health Care has assessed new treatments and warns that some new surgical techniques are being heavily promoted without first having been adequately evaluated.

Reviews in urology , Vol. 10, No. 1. , pp. 14-25. mtagaya bph Abstract Over the last 20 years, our understanding of the pathophysiology and symptomatology of men with lower urinary tract symptoms has become ...

The FDA has approved silodosin for treatment of benign prostatic hyperplasia. The drug, available as a once-daily capsule, blocks alpha-1 receptors in the prostate, bladder, and urethra, relaxing smooth muscle.

This review focuses on the different available options for treating benign prostatic hyperplasia in older men and on how to choose the right treatment.

Nobody knows why prostate glands decide to start growing as men hit middle age, but they do, frequently causing unjustified anxiety amongst its victims, who suspect that such an enlargement must be malignant.

Lowest Prices Guaranteed! ENTER HERE ONLINE! DISCOUNTS UP TO 70%!!! SPECIAL OFFERS.

Watson Pharmaceuticals Inc. announced Wednesday evening that FDA had approved the marketing of silodosin, or Rapaflo, to treat the signs and symptoms of benign prostatic hyperplasia.

The once-daily alpha blocker Rapaflo has been approved by the U.S. Food and Drug Administration to treat benign prostatic hyperplasia , the medical term for an enlarged prostate .

The company estimates the market for enlarged prostate treatments to be at least $2 billion a year.

Use of a class of medications for treating an enlarged prostate, known as 5- reductase inhibitors, are not associated with an increased hip fracture risk, according to a study in the October 8 issue of JAMA.